WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.

Faculty

Mohamad Mohty, MD, PhD

Professor
Hospital Saint Antoine
Sorbonne University
Paris, France

Disclosures

Consultant or advisor for: Amgen, Inc.; Celgene Corporation; Janssen; Jazz Pharmaceuticals, Inc.; Sanofi; Takeda
Speaker or member of speakers bureau for: Adaptive Biotechnologies; Amgen, Inc.; Astellas Pharma, Inc.; Celgene Corporation; Gilead Sciences, Inc.; Janssen; Jazz Pharmaceuticals, Inc.; Novartis; Oncopeptides AB; Pfizer, Inc.; Sanofi; Takeda
Research funding from: Janssen; Sanofi

Philippe Moreau, MD

University Professor of Clinical Hematology
Head
Hematology Department
University Hospital of Nantes
Nantes, France

Disclosures

Speaker or member of speakers bureau for: AbbVie, Inc.; Amgen, Inc.; Celgene Corporation; Janssen; Sanofi

Rakesh Popat, MD

University College London Hospitals
NHS Foundation Trust
London, United Kingdom

Disclosures

Consultant or advisor for: Amgen, Inc.; GlaxoSmithKline; Janssen
Speaker or member of speakers bureau for: AbbVie, Inc.; Bristol Myers Squibb Company; GlaxoSmithKline; Janssen
Research funding from: GlaxoSmithKline

Editors

Sanneke Koekkoek

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Sanneke Koekkoek, has no relevant financial relationships.

Eloise Ballard, PhD

Scientific Content Manager, WebMD Global, LLC

Disclosures

Disclosure: Eloise Ballard, PhD, has no relevant financial relationships.

Compliance Reviewer

Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

CPD

Multiple Myeloma: Practical Strategies for Managing Immunotherapy-Related Toxicities

Authors: Mohamad Mohty, MD, PhD; Philippe Moreau, MD; Rakesh Popat, MD
CPD Released: 4/1/2022
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 4/1/2023, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This educational activity is intended for an international audience of hematologists, oncologists, and ophthalmologists.

The goal of this activity is to provide physicians and other members of the multiple myeloma (MM) healthcare team with expert practical guidance in managing key toxicities associated with commonly used antimyeloma therapies.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Most common immunotherapy-related toxicities in patients with MM
Have greater competence related to
- The management of treatment-associated adverse events in patients with MM

Disclosures

Faculty

Mohamad Mohty, MD, PhD

Professor
Hospital Saint Antoine
Sorbonne University
Paris, France

Disclosures

Consultant or advisor for: Amgen, Inc.; Celgene Corporation; Janssen; Jazz Pharmaceuticals, Inc.; Sanofi; Takeda
Speaker or member of speakers bureau for: Adaptive Biotechnologies; Amgen, Inc.; Astellas Pharma, Inc.; Celgene Corporation; Gilead Sciences, Inc.; Janssen; Jazz Pharmaceuticals, Inc.; Novartis; Oncopeptides AB; Pfizer, Inc.; Sanofi; Takeda
Research funding from: Janssen; Sanofi

Philippe Moreau, MD

University Professor of Clinical Hematology
Head
Hematology Department
University Hospital of Nantes
Nantes, France

Disclosures

Speaker or member of speakers bureau for: AbbVie, Inc.; Amgen, Inc.; Celgene Corporation; Janssen; Sanofi

Rakesh Popat, MD

University College London Hospitals
NHS Foundation Trust
London, United Kingdom

Disclosures

Consultant or advisor for: Amgen, Inc.; GlaxoSmithKline; Janssen
Speaker or member of speakers bureau for: AbbVie, Inc.; Bristol Myers Squibb Company; GlaxoSmithKline; Janssen
Research funding from: GlaxoSmithKline

Editors

Sanneke Koekkoek

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Sanneke Koekkoek, has no relevant financial relationships.

Eloise Ballard, PhD

Scientific Content Manager, WebMD Global, LLC

Disclosures

Disclosure: Eloise Ballard, PhD, has no relevant financial relationships.

Compliance Reviewer

Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

Multiple Myeloma: Practical Strategies for Managing Immunotherapy-Related Toxicities

Authors: Mohamad Mohty, MD, PhD; Philippe Moreau, MD; Rakesh Popat, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 4/1/2022

Valid for credit through: 4/1/2023, 11:59 PM EST

processing....

A Powerpoint version of the slides from this presentation
is available for use as a professional resource from Medscape Education.

Download Now

CPD Information

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of WebMD Global, LLC or companies that support educational programming on medscape.org. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Faculty and Disclosures

Faculty

Mohamad Mohty, MD, PhD

Philippe Moreau, MD

Rakesh Popat, MD

Editors

Sanneke Koekkoek

Eloise Ballard, PhD

Compliance Reviewer

Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

Peer Reviewer

CPD

Multiple Myeloma: Practical Strategies for Managing Immunotherapy-Related Toxicities

Target Audience and Goal Statement

Disclosures

Faculty

Mohamad Mohty, MD, PhD

Philippe Moreau, MD

Rakesh Popat, MD

Editors

Sanneke Koekkoek

Eloise Ballard, PhD

Compliance Reviewer

Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Multiple Myeloma: Practical Strategies for Managing Immunotherapy-Related Toxicities